Literature DB >> 34272579

The pathophysiology of immunoporosis: innovative therapeutic targets.

Mouna Ferbebouh1, Francis Vallières1, Mohamed Benderdour1, Julio Fernandes2.   

Abstract

BACKGROUND: The physiological balance between bone resorption and bone formation is now known to be mediated by a cascade of events parallel to the classic osteoblast-osteoclast interaction. Thus, osteoimmunology now encompasses the role played by other cell types, such as cytokines, lymphocytes and chemokines, in immunological responses and how they help modulate bone metabolism. All these factors have an impact on the RANK/RANKL/OPG pathway, which is the major pathway for the maturation and resorption activity of osteoclast precursor cells, responsible for osteoporosis development. Recently, immunoporosis has emerged as a new research area in osteoimmunology dedicated to the immune system's role in osteoporosis.
METHODS: The first part of this review presents theoretical concepts on the factors involved in the skeletal system and osteoimmunology. Secondly, existing treatments and novel therapeutic approaches to treat osteoporosis are summarized. These were selected from to the most recent studies published on PubMed containing the term osteoporosis. All data relate to the results of in vitro and in vivo studies on the osteoimmunological system of humans, mice and rats.
FINDINGS: Treatments for osteoporosis can be classified into two categories. They either target osteoclastogenesis inhibition (denosumab, bisphosphonates), or they aim to restore the number and function of osteoblasts (romozumab, abaloparatide). Even novel therapies, such as resolvins, gene therapy, and mesenchymal stem cell transplantation, fall within this classification system.
CONCLUSION: This review presents alternative pathways in the pathophysiology of osteoporosis, along with some recent therapeutic breakthroughs to restore bone homeostasis.
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  Immunoporosis; Lymphocytes; Nanoparticles; Osteoblasts; Osteoclasts; Osteocytes; Osteoporosis; RANKL; Resolvins

Mesh:

Substances:

Year:  2021        PMID: 34272579     DOI: 10.1007/s00011-021-01484-9

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  112 in total

Review 1.  Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis.

Authors:  S C Manolagas
Journal:  Endocr Rev       Date:  2000-04       Impact factor: 19.871

Review 2.  Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems.

Authors:  Hiroshi Takayanagi
Journal:  Nat Rev Immunol       Date:  2007-04       Impact factor: 53.106

Review 3.  New factors controlling bone remodeling.

Authors:  P Marie; F Debiais; M Cohen-Solal; M C de Vernejoul
Journal:  Joint Bone Spine       Date:  2000       Impact factor: 4.929

4.  Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025.

Authors:  Russel Burge; Bess Dawson-Hughes; Daniel H Solomon; John B Wong; Alison King; Anna Tosteson
Journal:  J Bone Miner Res       Date:  2007-03       Impact factor: 6.741

Review 5.  Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis.

Authors:  S C Manolagas; R L Jilka
Journal:  N Engl J Med       Date:  1995-02-02       Impact factor: 91.245

Review 6.  Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families.

Authors:  T Suda; N Takahashi; N Udagawa; E Jimi; M T Gillespie; T J Martin
Journal:  Endocr Rev       Date:  1999-06       Impact factor: 19.871

7.  Screening, prevention and management of osteoporosis among Canadian adults.

Authors:  Siobhan O'Donnell
Journal:  Health Promot Chronic Dis Prev Can       Date:  2018-12       Impact factor: 3.240

Review 8.  Osteoporosis in men.

Authors:  Sundeep Khosla; Shreyasee Amin; Eric Orwoll
Journal:  Endocr Rev       Date:  2008-05-01       Impact factor: 19.871

9.  PTH differentially regulates expression of RANKL and OPG.

Authors:  John C Huang; Takeshi Sakata; Laura L Pfleger; Margaret Bencsik; Bernard P Halloran; Daniel D Bikle; Robert A Nissenson
Journal:  J Bone Miner Res       Date:  2003-12-16       Impact factor: 6.741

Review 10.  Epidemiology of osteoporotic fractures.

Authors:  Olof Johnell; John Kanis
Journal:  Osteoporos Int       Date:  2004-09-08       Impact factor: 4.507

View more
  2 in total

1.  MicroRNA-1270 Inhibits Cell Proliferation, Migration, and Invasion via Targeting IRF8 in Osteoblast-like Cell Lines.

Authors:  Eric Gustavo Ramírez-Salazar; Erika Victoria Almeraya; Tania Valentina López-Perez; Zacarías Jiménez-Salas; Nelly Patiño; Rafael Velázquez-Cruz
Journal:  Curr Issues Mol Biol       Date:  2022-03-01       Impact factor: 2.976

2.  Estradiol and zinc-doped nano hydroxyapatite as therapeutic agents in the prevention of osteoporosis; oxidative stress status, inflammation, bone turnover, bone mineral density, and histological alterations in ovariectomized rats.

Authors:  Mona M Elghareeb; Gehad E Elshopakey; Tarek A Elkhooly; Basma Salama; Alaa Samy; Fuller W Bazer; Mohammed A Elmetwally; Mikhlid H Almutairi; Lotfi Aleya; Mohamed M Abdel-Daim; Shaymaa Rezk
Journal:  Front Physiol       Date:  2022-09-19       Impact factor: 4.755

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.